Thermo Fisher Scientific Inc. (TMO) Carries a Mid-Single Digit Organic Growth Forecast
On January 30, Daniel Arias of Stifel Nicolaus maintained a Buy rating on Thermo Fisher Scientific Inc. (NYSE:TMO), with a $700 price target.
Thermo Fisher Scientific Inc. (TMO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 2,792,421 | $1,618,068,956 | +3% | 0.55% |
| 2. | Unisphere Establishment Hani Lazkani (Ceo) | 1,960,000 | $1,135,722,000 | -5% | 8.49% |
| 3. | Generation Investment Management David Blood And Al Gore | 1,111,327 | $643,958,429 | -14% | 4.47% |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 953,828 | $552,695,634 | +89% | 0.5% |
| 5. | Cantillon Capital Management William Von Mueffling | 873,322 | $506,046,433 | +1% | 2.74% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $535.93 | 4 | $2,143.73 | 14,268 | 2024-12-09 | Filing | |
| $555.89 | 16 | $8,894.24 | 14,264 | 2024-11-07 | Filing | |
| $526.15 | 4 | $2,104.60 | 13,101 | 2023-06-26 | Filing | |
| $134.16 | 1,000 | $134,160.00 | 14,636 | 2015-12-11 | Filing | |
| $45.84 | 36 | $1,650.24 | 25,914 | 2010-08-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $541.20 | 400 | $216,480.00 | 20,752 | 2026-02-09 | Filing | |
| $563.56 | 22,046 | $12,424,243.76 | 84,117 | 2025-12-04 | Filing | |
| $584.11 | 2,521 | $1,472,541.31 | 65,480 | 2025-12-03 | Filing | |
| $583.33 | 29,479 | $17,195,985.07 | 68,001 | 2025-12-03 | Filing | |
| $581.92 | 30,000 | $17,457,600.00 | 29,480 | 2025-12-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 34,133,702 | $19,778,773,624 | 0.29% | |
| 2. | 30,677,885 | $17,776,300,029 | 0.3% | |
| 3. | 16,613,761 | $9,633,990,730 | 0.32% | |
| 4. | 11,894,277 | $6,892,141,169 | 0.41% | |
| 5. | 11,003,814 | $6,376,229,130 | 0.87% |
News See All
11 Best Stocks In Each Sector in 2026
As we step into 2026, investors are increasingly seeking clarity in a complex market landscape.
10 Best Life Sciences Stocks to Buy According to Hedge Funds
Following a difficult start in 2025, the ever-evolving life sciences segment recovered strongly in the latter half of the year.
Will Thermo Fisher Scientific (TMO) Benefit from Favorable Trends in the Market?
Baron Funds, an investment management company, released its fourth-quarter investor letter for the “Baron Health Care Fund”. A copy of the letter can be downloaded here.
Thermo Fisher Scientific Inc. (NYSE:TMO) Q4 2025 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2025 Fourth Quarter Conference Call.
Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory
We came across a bullish thesis on Thermo Fisher Scientific Inc. on Rijnberk InvestInsights’s Substack by Daan | InvestInsights. In this article, we will summarize the bulls’ thesis on TMO.
Thermo Fisher Scientific Inc. (TMO) and NVIDIA Partner to Bring Advanced AI to Lab Workflows
TheFly reported on January 9 that Stifel analyst Daniel Arias maintained a Buy rating on TMO and significantly raised the price target to $700 from $583, an increase of $117.
10 Best Investments During A Recession
As of early 2026, the U.S. economy is in a fragile “stagflation-lite” phase, balancing resilient growth against an elevated risk of recession. According to major financial organizations like J.P.
Here’s What Lifted Thermo Fisher Scientific (TMO) in Q3
Bristol Gate Capital Partners, an investment management company, published its Q3 2025 investor letter for the “US Equity Strategy”. A copy of the letter can be downloaded here.
BofA Raises Thermo Fisher (TMO) Target as Biopharma Recovery Comes Into View
On December 15, Bank of America raised its price target on Thermo Fisher Scientific Inc. (NYSE:TMO) to $700 from $650 and kept a Buy rating on the shares.
Hedge Fund Resource Center